Skip to main content
SpringerLink
Log in

Inherited Gene Mutations in Gynecological Oncology

  • Chapter
  • First Online:
Pelvic Cancer Surgery

  • 1937 Accesses

Abstract

Up to 10 % of some types of gynecological cancer can be attributed to a genetic predisposition. Women at high-risk of these cancers because of their family history or a germline mutation may be offered risk-reducing surgery. Those at risk of ovarian/tubal cancer should be offered bilateral salpingo-oophorectomy, but Lynch syndrome carriers at risk of ovarian and endometrial cancer should also be offered hysterectomy. Specialist histopathology protocols are mandatory to avoid missing occult cancers. Risk-reducing surgery prevents gynecological cancers and may reduce breast cancer risk when performed premenopausally. Familial risk assessment and decision-making around genetic testing is complex and requires clinical genetics advice. Furthermore, risk-reducing surgery may lead to premature menopause and loss of fertility, so women may require advice from colleagues in other specialties. Surveillance for familial gynecological cancers is of unproven benefit and women considering screening should be aware of its limitations. Use of the oral contraceptive pill, breastfeeding and a healthy lifestyle may reduce the risk of inherited gynecological cancers, but surgery is the primary preventative option.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E, Siminovsky Y, Abeliovich D, Peretz T, Simon A, Laufer N. Preimplantation genetic diagnosis for BRCA1/2–a novel clinical experience. Prenat Diagn. 2009;29:508–13.

    Article  CAS  PubMed  Google Scholar 

  2. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–51.

    Article  CAS  PubMed  Google Scholar 

  3. Soegaard M, Jensen A, Frederiksen K, Høgdall E, Høgdall C, Blaakaer J, Kjaer SK. Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. Cancer Causes Control. 2008;19:469–79.

    Article  PubMed  Google Scholar 

  4. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B, Bishop DT, Easton DF. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10:2473–81.

    Article  CAS  PubMed  Google Scholar 

  5. Kerr B, Foulkes WD, Cade D, Hadfield L, Hopwood P, Serruya C, Hoare E, Narod SA, Evans DG. False family history of breast cancer in the family cancer clinic. Eur J Surg Oncol. 1998;24:275–9.

    Article  CAS  PubMed  Google Scholar 

  6. Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011;118:814–24.

    Article  CAS  PubMed  Google Scholar 

  7. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ. Results of annual screening in the UK familial ovarian cancer screening study (UK FOCSS phase 1) highlight need for strict adherence to screening schedule. J Clin Oncol. 2013;31:49–57.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Manchanda R, Saridogan E, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Side L, Gessler S, Jacobs I, Menon U. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet. 2012;286:1555–62.

    Article  PubMed  Google Scholar 

  9. Brain KE, Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancastle D, Phelps C, Watson EK, Clements A, Menon U. Psychological outcomes of familial ovarian cancer screening: no evidence of long-term harm. Gynecol Oncol. 2012;127:556–63.

    Article  PubMed  Google Scholar 

  10. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3–9.

    Article  PubMed  Google Scholar 

  11. Manchanda R, Silvanto A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, Menon U, Benjamin E. Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy. Int J Gynecol Cancer. 2012;22(5):881–8.

    Article  PubMed  Google Scholar 

  12. Manchanda R, Drapkin R, Jacobs I, Menon U. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol. 2012;124:185–91.

    Article  PubMed  Google Scholar 

  13. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491–6.

    Article  PubMed  Google Scholar 

  14. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van’t Veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–27.

    Article  CAS  PubMed  Google Scholar 

  17. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83:211–7.

    Article  CAS  PubMed  Google Scholar 

  18. Finch A, Evans DG, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health. 2012;8:543–55.

    CAS  Google Scholar 

  19. Recovering well – information for you after a laparoscopy. https://www.rcog.org.uk/globalassets/documents/patients/patient-information-leaflets/recovering-well/laparoscopy-recovering-well.pdf.

  20. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA, Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013;130:127–31.

    Google Scholar 

  21. Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M, Boardman LA. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hereditary Cancer Clin Pract. 2010;8:6.

    Article  Google Scholar 

  22. Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol. 2011;118:1271–9.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause. 2011;18:956–61.

    Article  PubMed  Google Scholar 

  24. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. National Institute for Health and Care Excellence (NICE) guideline, June 2013. https://www.nice.org.uk/guidance/cg164.

  25. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008;9:1191–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46:2275–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Women’s Health, University College London Hospitals NHS Foundation Trust & Department of Women’s Cancer, UCL EGA Institute for Women’s Health, London, UK

    Adam N. Rosenthal PhD, MRCOG

  2. Department of Women’s Cancer, UCL EGA Institute for Women’s Health & North East Thames Regional Genetics Service, Great Ormond Street Hospital, London, UK

    Lucy E. Side MD, MB, BCh

Authors
  1. Adam N. Rosenthal PhD, MRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucy E. Side MD, MB, BCh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam N. Rosenthal PhD, MRCOG .

Editor information

Editors and Affiliations

  1. Urology, University Hospital of North Norway, Tromsø, Norway

    Hitendra R.H. Patel

  2. University College London Hospital, London, United Kingdom

    Tim Mould

  3. Laparoscopic and Robotic Surgery, University of Rochester Medical Center, Rochester, New York, USA

    Jean V. Joseph

  4. Colorectal Surgery, University Hospitals Case Medical Center, Cleveland, Ohio, USA

    Conor P. Delaney

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Rosenthal, A.N., Side, L.E. (2015). Inherited Gene Mutations in Gynecological Oncology. In: Patel, H., Mould, T., Joseph, J., Delaney, C. (eds) Pelvic Cancer Surgery. Springer, London. https://doi.org/10.1007/978-1-4471-4258-4_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4258-4_27

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4257-7

  • Online ISBN: 978-1-4471-4258-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation